EMBC Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 5.1% compared to Embecta's net margin of 11.12%. Embecta's return on equity of -- beat Boston Scientific's return on equity of 8.91%.

Embecta has a consensus price target of $21.05, signalling upside risk potential of 2.63%. On the other hand Boston Scientific has an analysts' consensus of $99.42 which suggests that it could grow by 9.62%. Given that Boston Scientific has higher upside potential than Embecta, analysts believe Boston Scientific is more attractive than Embecta.

Embecta has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.800, suggesting its less volatile than the S&P 500 by 20.007%.

Embecta has a quarterly dividend of $0.15 per share corresponding to a yield of 2.93%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Embecta pays 44.06% of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Embecta quarterly revenues are $286.1M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Embecta's net income of $14.6M is lower than Boston Scientific's net income of $468M. Notably, Embecta's price-to-earnings ratio is 15.19x while Boston Scientific's PE ratio is 74.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Embecta is 1.06x versus 8.45x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies has a net margin of 5.1% compared to Embecta's net margin of -31.3%. Embecta's return on equity of -- beat iRhythm Technologies's return on equity of -108.99%.

Embecta has a consensus price target of $21.05, signalling upside risk potential of 2.63%. On the other hand iRhythm Technologies has an analysts' consensus of $100.92 which suggests that it could grow by 16.26%. Given that iRhythm Technologies has higher upside potential than Embecta, analysts believe iRhythm Technologies is more attractive than Embecta.

Embecta has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.257, suggesting its more volatile than the S&P 500 by 25.744%.

Embecta has a quarterly dividend of $0.15 per share corresponding to a yield of 2.93%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Embecta pays 44.06% of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend. Embecta's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Embecta quarterly revenues are $286.1M, which are larger than iRhythm Technologies quarterly revenues of $147.5M. Embecta's net income of $14.6M is higher than iRhythm Technologies's net income of -$46.2M. Notably, Embecta's price-to-earnings ratio is 15.19x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Embecta is 1.06x versus 5.03x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Inari Medical has a net margin of 5.1% compared to Embecta's net margin of -11.97%. Embecta's return on equity of -- beat Inari Medical's return on equity of -17.68%.

Embecta has a consensus price target of $21.05, signalling upside risk potential of 2.63%. On the other hand Inari Medical has an analysts' consensus of $64.38 which suggests that it could grow by 33.79%. Given that Inari Medical has higher upside potential than Embecta, analysts believe Inari Medical is more attractive than Embecta.

Embecta has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inari Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Embecta has a quarterly dividend of $0.15 per share corresponding to a yield of 2.93%. Inari Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Embecta pays 44.06% of its earnings as a dividend. Inari Medical pays out -- of its earnings as a dividend. Embecta's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Embecta quarterly revenues are $286.1M, which are larger than Inari Medical quarterly revenues of $153.4M. Embecta's net income of $14.6M is higher than Inari Medical's net income of -$18.4M. Notably, Embecta's price-to-earnings ratio is 15.19x while Inari Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Embecta is 1.06x versus 5.03x for Inari Medical. Usually stocks with elevated PS ratios are considered overvalued.

Nevro has a net margin of 5.1% compared to Embecta's net margin of -15.83%. Embecta's return on equity of -- beat Nevro's return on equity of -24.66%.

Embecta has a consensus price target of $21.05, signalling upside risk potential of 2.63%. On the other hand Nevro has an analysts' consensus of $5.96 which suggests that it could grow by 53.19%. Given that Nevro has higher upside potential than Embecta, analysts believe Nevro is more attractive than Embecta.

Embecta has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nevro has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.064%.

Embecta has a quarterly dividend of $0.15 per share corresponding to a yield of 2.93%. Nevro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Embecta pays 44.06% of its earnings as a dividend. Nevro pays out -- of its earnings as a dividend. Embecta's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Embecta quarterly revenues are $286.1M, which are larger than Nevro quarterly revenues of $96.9M. Embecta's net income of $14.6M is higher than Nevro's net income of -$15.3M. Notably, Embecta's price-to-earnings ratio is 15.19x while Nevro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Embecta is 1.06x versus 0.33x for Nevro. Usually stocks with elevated PS ratios are considered overvalued.